公开(公告)号：WO2022040586A2

公开(公告)日：2022-02-24

申请号：PCT/US2021/046994

申请日：2021-08-20

申请人： NOVARTIS AG

发明人： KOSHY, Sandeep Tharian ,  DRANOFF, Glenn ,  BROGGI, Maria Anna Sofia ,  BRIDGEMAN, Chris ,  CANHAM, Stephen Michael ,  MELLES, Yoel ,  CEBE, Regis ,  GRANDA, Brian Walter ,  TREANOR, Louise Mary ,  JAYASHANKAR, Shyamali ,  YANG, Jennifer ,  RAYO, Amy ,  PRICE, Andrew Patrick ,  SKEGRO, Darko ,  GUYOT, Justine ,  APSUNDE, Tushar Dattu ,  LEE, Cameron Chuck-munn ,  BARDROFF, Michael ,  MILLER, Sandra

IPC分类号： A61K39/00 ,  A61P35/00 ,  C07K14/49 ,  C07K14/725 ,  A61K48/00 ,  A61K38/18 ,  A61K47/59 ,  A61K9/00 ,  A61K47/69 ,  A61K47/61 ,  A61K2039/505 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K2039/804 ,  A61K38/1866 ,  A61K39/001104 ,  A61K39/001112 ,  A61K47/6901 ,  A61K47/6903 ,  A61K47/6923 ,  A61K47/6929 ,  A61K48/0008 ,  A61K9/0019 ,  C07K14/7051 ,  C07K2319/03

摘要： Aspects of this disclosure relate generally to the use of biomaterials for the in vivo generation of CAR expressing cells. In some embodiments, the biomaterials comprise one or more of a cell recruitment composition, a viral vector, and/or a cell activation agent.

公开(公告)号：WO2022022719A1

公开(公告)日：2022-02-03

申请号：PCT/CN2021/109864

申请日：2021-07-30

申请人： 北京市神经外科研究所

发明人： 张伟 ,  江涛 ,  翟优 ,  李冠璋

IPC分类号： C07K14/715 ,  C12N15/12 ,  C07K19/00 ,  C12N15/62 ,  C12N15/867 ,  C12N5/10 ,  A61K39/00 ,  A61P35/00 ,  A61K2039/5158 ,  A61K39/001119 ,  C07K14/7155 ,  C07K16/2884 ,  C07K16/2896 ,  C07K2317/622 ,  C07K2319/03 ,  C12N15/86 ,  C12N2510/00 ,  C12N2740/15043 ,  C12N5/0636

摘要： 本发明提供了一种IL7Rα的截短体，该IL7Rα的截短体的氨基酸序列包含SEQ ID NO.1所示的序列；表达含有上述IL7Rα截短体的嵌合抗原受体的T细胞，能够有效杀伤肿瘤细胞。

公开(公告)号：WO2022003138A1

公开(公告)日：2022-01-06

申请号：PCT/EP2021/068267

申请日：2021-07-01

申请人： TCER ONCOLOGY AB

发明人： GRÖNLUND, Hans ,  KIESSLING, Rolf ,  WICKSTRÖM, Stina

IPC分类号： A61K35/15 ,  A61K39/00 ,  C12N5/0784 ,  A61K2039/5154 ,  A61K2039/5158 ,  A61K39/0011 ,  C12N2502/1114 ,  C12N2502/1121 ,  C12N5/0638 ,  C12N5/0639

摘要： The present invention provides an in vitro method for the manufacture of a dendritic cell (DC) cancer vaccine, said method comprising the steps of: (i) providing a plurality of phagocytosable particles, wherein each phagocytosable particle comprises a core and an antigenic construct tightly associated to the core, wherein the antigenic construct comprises at least one epitope peptide having an amino acid sequence corresponding to an amino acid sequence of a part of a protein or peptide known or suspected to be expressed by a cancer cell in a subject; (ii) providing a sample of DCs; and (iii) contacting the sample of DCs with the plurality of phagocytosable particles in vitro and under conditions allowing for the phagocytosis of at least one phagocytosable particle by a DC. The present invention also provides a DC cancer vaccine produced by the method of the invention, and the use a DC cancer vaccine of the invention as a medicament and for the ex vivo expansion of anticancer T-cells.

公开(公告)号：WO2021260657A1

公开(公告)日：2021-12-30

申请号：PCT/IB2021/055715

申请日：2021-06-25

申请人： CRISPR THERAPEUTICS AG

发明人： TERRETT, Jonathan Alexander ,  KALAITZIDIS, Demetrios ,  MORAWA, Ewelina ,  BENTON, Mark

IPC分类号： A61K35/17 ,  A61K39/00 ,  A61K39/395 ,  A61P35/00 ,  A61P35/02 ,  C07K14/705 ,  C07K16/28 ,  C12N5/0783 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K2039/545 ,  A61K2039/804 ,  A61K39/001112 ,  C07K14/7051 ,  C07K16/2803 ,  C07K16/2896 ,  C07K2319/03

摘要： Methods for treating a B cell malignancy comprising a population of genetically engineered immune cells (e.g., T cells), which express a chimeric antigen receptor (CAR) specific to CD19 and optionally an NK cell inhibitor (e.g., daratumumab). The genetically engineered immune cells may comprise a disrupted TRAC gene, a disrupted β2M gene, or both.

公开(公告)号：WO2021260186A1

公开(公告)日：2021-12-30

申请号：PCT/EP2021/067505

申请日：2021-06-25

申请人： JUNO THERAPEUTICS GMBH

发明人： POLTORAK, Mateusz Pawel ,  STEMBERGER, Christian ,  GERMEROTH, Lothar

IPC分类号： A61K39/00 ,  A61K35/17 ,  C12N15/90 ,  C12N5/0783 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K2039/804 ,  A61K39/001112 ,  A61K48/005 ,  A61P35/00 ,  C07K14/7051 ,  C07K2319/03 ,  C12N15/907 ,  C12N2740/16043 ,  C12N2750/14143 ,  C12N2840/203

摘要： Provided are engineered T cells that contain a modified T cell stimulation-associated locus encoding a recombinant receptor or a portion thereof. In some aspects, the nucleic acid sequence encoding the recombinant receptor or a portion thereof is operably linked to an endogenous transcriptional regulatory element of the T cell stimulation-associated locus, in some cases, engineered by targeted integration. In some aspects, the engineered cells conditionally express the recombinant receptor, such as upon stimulation or activation signal in the T cell. Also disclosed are cell compositions, nucleic acids for engineering cells, and methods and articles of manufacture for producing the engineered cells. In some embodiments, the engineered cells can be used in connection with cell therapy, including in connection with cancer immunotherapy comprising adoptive transfer of the engineered cells.

公开(公告)号：WO2021147121A1

公开(公告)日：2021-07-29

申请号：PCT/CN2020/074252

申请日：2020-02-04

申请人： 中国科学院动物研究所

发明人： 赵同标 ,  靳利远 ,  朱颖婕 ,  曹磊 ,  曹佳妮 ,  李晓燕

IPC分类号： C12N5/10 ,  C12N15/12 ,  C12N15/63 ,  C12N15/62 ,  A61K35/17 ,  A61P35/00 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K39/0011 ,  A61K39/001104 ,  A61K39/001142 ,  C07K14/523 ,  C07K14/7051 ,  C07K14/70521 ,  C07K16/2863 ,  C07K2317/622 ,  C07K2319/00 ,  C07K2319/03 ,  C07K2319/33 ,  C07K2319/74 ,  C12N15/86 ,  C12N2510/00 ,  C12N2740/15043 ,  C12N2800/107 ,  C12N5/0636 ,  C12N5/0645 ,  C12N5/0646

摘要： 提供了基因修饰的免疫细胞，该免疫细胞表达嵌合抗原受体并过表达趋化因子受体CCR6，增强了免疫细胞在实体肿瘤处的归巢和聚集以及实体瘤浸润，进而增强了免疫细胞对于实体肿瘤的治疗效果。还提供了修饰免疫细胞的方法和免疫细胞在制备治疗肿瘤的药物中的应用。

公开(公告)号：WO2021123802A1

公开(公告)日：2021-06-24

申请号：PCT/GB2020/053280

申请日：2020-12-18

申请人： AUTOLUS LIMITED

发明人： GANNON, Isaac ,  SMITH, Paul ,  THOMAS, Simon ,  PULÉ, Martin

IPC分类号： C12N9/02 ,  A61K39/00 ,  C07K14/725 ,  A61K2039/5156 ,  A61K2039/5158 ,  C07K14/7051 ,  C07K2319/03 ,  C12N2501/71 ,  C12N5/0636 ,  C12N9/0008

摘要： The present invention relates to a cell which expresses a chimeric antigen receptor (CAR) or a transgenic T-cell receptor (TCR) and an isoform of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) that is resistant to inhibition by one or more glycolysis inhibitors.

公开(公告)号：WO2020187340A2

公开(公告)日：2020-09-24

申请号：PCT/CU2020/050002

申请日：2020-03-09

申请人： CENTRO DE INMUNOLOGIA MOLECULAR ,  LUDWIG INSTITUTE FOR CANCER RESEARCH LTD ,  CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS ,  UNIVERSITY OF LAUSANNE

发明人： LEÓN MONZÓN, Kalet ,  MONTALVO BEREAU, Galia Magela ,  COUKOS, George ,  IRVING, Melita ,  CRIBIOLI, Elisabetta ,  ORTIZ MIRANDA, Yaquelín ,  CORRIA OSORIO, Ángel de Jesús

IPC分类号： C12N5/0783 ,  A61K39/00 ,  C07K14/55 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K39/0011 ,  C12N2501/2302 ,  C12N2501/2307 ,  C12N2501/2315 ,  C12N5/0638 ,  C12N5/0646

摘要： En la presente invención se describe un método para obtener linfocitos T y células NK con el fenotipo deseado en la transferencia adoptiva de células para la terapia del cáncer. Especialmente, se basa en estrategias para inducir una señalización preferencial a través del receptor de IL2 de afinidad intermedia, con lo cual se logra expandir las células con el fenotipo de memoria central deseado. El método de la presente invención es útil en la obtención de linfocitos infiltrantes de tumor, TCR o de receptores quiméricos ingenierizados de células T empleados en el tratamiento del cáncer.

公开(公告)号：WO2020181240A1

公开(公告)日：2020-09-10

申请号：PCT/US2020/021508

申请日：2020-03-06

申请人： GRITSTONE ONCOLOGY, INC.

发明人： BOUCHER, Thomas Francis ,  BULIK-SULLIVAN, Brendan ,  BUSBY, Jennifer ,  CAO, Minh Duc ,  DAVID, Matthew Joseph ,  YOUNG, Lauren Elizabeth ,  FRANCIS, Joshua Michael ,  PALMER, Christine ,  SKOBERNE, Mojca ,  YELENSKY, Roman

IPC分类号： G06N3/02 ,  G06F17/00 ,  A61K35/17 ,  A61K35/15 ,  A61K39/00 ,  A61K38/10 ,  C07K7/08 ,  C12N5/00 ,  A61K2039/5158 ,  C12Q1/6886 ,  C12Q2600/136 ,  G01N33/56977 ,  G01N33/57484 ,  G01N33/6878 ,  G06N3/0445 ,  G06N3/0454 ,  G06N3/0481 ,  G06N3/08 ,  G06N3/082 ,  G16B20/00 ,  G16B40/20

摘要： A method for identifying T-cells that are antigen-specific for at least one neoantigen that is likely to be presented by class II MHC alleles on surfaces of tumor cells of a subject. Peptide sequences of tumor neoantigens are obtained by sequencing the tumor cells of the subject. The peptide sequences are input into a machine-learned presentation model to generate presentation likelihoods for the tumor neoantigens, each presentation likelihood representing the likelihood that a neoantigen is presented by the class II MHC alleles on the surfaces of the tumor cells of the subject. A subset of the neoantigens is selected based on the presentation likelihoods. T-cells that are antigen-specific for at least one of the neoantigens in the subset are identified. These T-cells can be expanded for use in T-cell therapy. TCRs of these identified T-cells can also be sequenced and cloned into new T-cells for use in T-cell therapy.

公开(公告)号：WO2020051374A1

公开(公告)日：2020-03-12

申请号：PCT/US2019/049816

申请日：2019-09-05

申请人： POSEIDA THERAPEUTICS, INC.

发明人： OSTERTAG, Eric M. ,  SHEDLOCK, Devon

IPC分类号： C07K19/00 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K35/17 ,  A61K39/0011 ,  A61P37/02 ,  C07K14/70507 ,  C07K14/7051 ,  C07K2319/03 ,  C07K2319/33

摘要： Disclosed are chimeric stimulatory receptors (CSRs), cell compositions comprising CSRs, methods of making and methods of using same for the treatment of a disease or disorder in a subject.